Clinical Trial Search

Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Overall ObjectiveResponse (ORR) Rate — 0; 7; 19; 4 participants

Primary: Number of Participants (Par.) With Response as Assessed by the Investigator — 31 participants

Primary: Overall Response Rate as Assessed According to the"Revised Response Criteria for Malignant Lymphoma" (Cheson 2007). — 5; 2; 7; 1 Participants

Primary: Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC) — 67.8; 70.0; 68.1 percentage…

Primary: Percentage of Participants With Relapsed or Refractory DLBCL Who Are Progression-Free for at Least 2 Cycles (28-Day Cycles) After Receiving Enzastaurin (LY317615)…

Primary: Number of Participants With at Least One Dose Limiting Toxicity (DLT) — 3; 1; 0; 0 Participants

Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants

Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants

Primary: Survival at 1 Year After Transplantation — 10; 6 participants

Primary: Number of Participants (Par.) With Confirmed Response as Assessed by the Investigator — 21; 8 participants

Primary: Part 1 and Part 2: Number of Participants With Adverse Events — 3; 4; 5; 274 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 29; 49; 11; 15 participants

Primary: Number of Participants (Par.) During Initial Treatment Exposed to the Indicated Dose Levels of the Therapeutic Dose (TD), Re-dose, and Total Dose (TD + Re-dose) — 6; 1…

Primary: 3 Years Event-free Survival — 51; 56; 126; 123 Participants

Primary: Number of Participants With Confirmed Response, Including Participants With Complete Response (CR), Clinical Complete Response (CCR), and Partial Response (PR) — 72…

Primary: Objective Tumor Response — 0 participants

Primary: The Overall Response Rate [Complete Response (CR) + Partial Response (PR)] Determined on the Basis of Revised Response Criteria for Malignant Lymphoma — 62.7 Percentage…

Primary: Complete Response Rate (CRR) — 73 Percentage of patients

Primary: Number of Participants With Unconfirmed Response (Complete Response or Partial Response) and Unconfirmed Complete Response — 437; 238 Participants

Primary: Complete Response (CR) and Complete Response Unconfirmed (CRu) — 20.0; 5.7; 24.3; 7.1 percentage of randomized patients

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Event-free Survival — 16 Participants

Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…

Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0 Participants

Primary: Overall Response Rate — 81.8 Percentage

Primary: Number of Participants With the Indicated Grade 4 Hematology Toxicities Following Iodine-131 Anti-B1 Antibody — 1; 1; 1; 1 participants

Primary: Objective Response Rate — 2; 0 Patients

Primary: To Evaluate the Overall Response Rate (ORR) of Brentuximab Vedotin in EBV- and CD30-positive Lymphomas — 12 Participants